Linden Thomas Advisory Services, LLC Incyte Corp Transaction History

Linden Thomas Advisory Services, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	BUY	$60.95 - $75.51 $68,446 - $84,797	1,123 Added 10.25%	12,081 $752 Million
Q1 2023 Apr 24, 2023	SELL	$70.23 - $86.01 $1,685 - $2,064	-24 Reduced 0.22%	10,958 $792 Million
Q4 2022 Feb 16, 2023	BUY	$67.18 - $84.11 $737,770 - $923,696	10,982 New	10,982 $882 Million

659

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Linden Thomas Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Linden Thomas Advisory Services, LLC with notifications on news.